Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Monia Brett P						2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONIS]									all applic Directo Officer	cable) r (give title	g Pers	son(s) to Issu 10% Ow Other (s	vner
(Last) 2855 GA	Last) (First) (Middle) 855 GAZELLE COURT						3. Date of Earliest Transaction (Month/Day/Year) 11/23/2018									below) below) Chief Operating Officer			
(Street) CARLSBAD CA 92010 (City) (State) (Zip)				4. 	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indiv ine) X	Form f	r Joint/Group Filing (Check Applicable In filed by One Reporting Person In filed by More than One Reporting In filed by More than One Reporting				
		Tab	le I - I	Non-Der	ivativ	e Sec	curities	s Ac	cquire	ed, D	isposed o	f, or B	eneficia	ally (Owned				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/					Execution Date,		"	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			Benefici Owned F		es For ially (D) Following (I)		n: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								ľ	Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)		1	Instr. 4)
Common	on Stock			11/23/2	2018	11/	/23/2018		M ⁽¹⁾		34,000(1)	Α	\$14.6	59	49,841			D	
Common	Stock			11/23/2	2018	11/	/23/201	8	S ⁽¹⁾		34,000(1)	D	\$55.00	1 ⁷⁽²⁾	15	,841		D	
		-	Table								posed of, , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira	te Exerc ation D th/Day/		7. Title and Ame of Securities Underlying Derivative Secu (Instr. 3 and 4)		De Se	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amoun or Numbe of Shares	r					
Employee Stock Option (right to	\$14.69	11/23/2018	11/2	23/2018	М		34,000		01/02	2/2017	01/29/2020	Common Stock	34,00	0	\$0	0		D	

Explanation of Responses:

1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018.

Remarks:

/s/Patrick R. O'Neil, attorney-

11/26/2018

in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} The price reported in Column 4 is a weighted average price. These share were sold in multiple transactions at prices ranging from \$55.00 to \$55.08, inclusive The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.